Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
10.1016/j.expneurol.2020.113359 Exp
101 Enhanced DNA damage repair mechanisms contribute similarly: in BRCA2-deficient tumors, reduced EZH2 expression stabilizes replication forks, diminishing sensitivity to PARP inhibitors (PARPis)
8,9 With regard to excretion , half-life is not affected by renal disease for drugs that are metabolized by the liver
In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
Yes, in research
US$ 26.18
US$ 28.12
US$ 25.84
US$ 24.23
